Breast cancer screening and diagnostics in the United States have entered a new era, powered by advanced imaging technologies that prioritize early detection, high diagnostic accuracy, and personalized care. With rising awareness and government support for women’s health, the U.S. breast cancer screening market is rapidly evolving—especially in addressing the unique needs of women with dense breast tissue. These advancements are not only improving clinical outcomes but are also fueling robust growth across the U.S. breast imaging equipment and diagnostic technologies market.
2D digital mammography remains the most common screening tool, offering broad accessibility and familiarity among providers. By 2021, digital systems replaced older film-based setups in nearly 90% of procedures in the U.S. This method captures two-dimensional images of compressed breast tissue, which can be effective for early cancer detection. However, 2D digital mammography limitations particularly in dense breast tissue where overlapping structures obscure visibility—have spurred the rise of more advanced imaging modalities. Hologic and Siemens Healthineers are major providers of digital mammography systems, offering scalable platforms for hospitals and outpatient clinics.
Also known as 3D mammography, Digital Breast Tomosynthesis (DBT) has emerged as a game-changer. It uses multiple angled X-ray images to construct a three-dimensional view of the breast, significantly improving detection in dense tissues. Approved by the FDA in 2011, DBT has shown a 20–30% improvement in cancer detection compared to 2D mammography and has reduced call-back rates by 15–30%. By 2023, it accounted for nearly 50% of the image-based screening market in the U.S. Hologic dominates the DBT segment with its Selenia Dimensions system. Also, GE Healthcare and FujiFilm Medical Systems also offer FDA-approved 3D mammography platforms.
Also Read: From Detection to Therapy: AI's Impact on the Next Era of Cancer Care
Contrast-Enhanced Digital Mammography (CEDM) represents a significant leap by incorporating contrast agents to visualize abnormal blood flow linked to tumors. The ongoing Contrast-Enhanced Mammography Imaging Screening Trial (CMIST), led by the American College of Radiology in collaboration with GE Healthcare, is evaluating CEDM’s performance in women with dense breasts, estimated to be 43% of women aged 40–72. Early results suggest it could outperform DBT in specificity, potentially reducing false positives. GE Healthcare is the lead innovator in CEDM and a key sponsor of CMIST.
Get to Know More Insights on US Breast Cancer Screening and Diagnostics
Ultrasound is widely used as an adjunct to mammography, especially for evaluating dense breast tissue or guiding biopsies. It is cost-effective and accessible, although it has a higher false-positive rate. A landmark 2012 study by the University of Pittsburgh revealed that ultrasound detected 53% of breast cancers, showing performance comparable to mammography. Samsung Medison, Philips, and GE Healthcare offer advanced ultrasound platforms optimized for breast imaging.
MRI remains the most sensitive imaging method, especially for high-risk populations like BRCA mutation carriers. Using specialized coils and contrast agents, breast MRI achieves 90–95% sensitivity. While cost and access limit its use as a general screening tool, technological improvements in coil design and metabolic imaging make it indispensable for advanced diagnostics. Siemens Healthineers, Canon Medical Systems, and GE Healthcare lead in breast MRI innovations.
As the U.S. advances toward personalized medicine, these technologies supported by industry leaders are reshaping how breast cancer is detected and treated. With continued investment in clinical trials, smart imaging systems, and AI integration, the future of breast cancer screening promises earlier, safer, and more accurate diagnosis for millions.
Looking to enter a new market but unsure where to start? At BIS Research, we provide first-hand insights directly from key opinion leaders (KOLs), backed by rigorous primary and secondary research. Whether you're exploring opportunities in computed tomography (CT), positron emission tomography (PET), or single photon emission computed tomography (SPECT) of U.S. breast cancer screening and diagnostic market, our segmentation-driven approach helps you tap into real market growth potential. Our strategic intelligence empowers you to make informed, confident decisions—from product positioning to pricing and regulatory planning
